Status:
COMPLETED
Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
Lead Sponsor:
University of Southern California
Collaborating Sponsors:
Novartis
Conditions:
Colon Cancer
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study is for people with solid tumors cancer for which the standard chemotherapy drugs have not worked. The purpose of this research is to evaluate the side effects of Xeloda (also called capecit...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed metastatic or unresectable solid tumor for which standard curative or palliative measures do not exist or are no longer effective.
- SWOG performance status 0-2.
- ANC greater than 1500, platelets greater than 100,000.
- Total bilirubin less than 2 x upper limit of normal, or less than 3 x upper limit of normal in patients with liver metastasis. Transaminase (AST and/or ALT) less than 2 x upper limit of normal or less than 3 x upper limit of normal in patients with liver metastasis.
- Serum creatinine less than 1.25 x institutional upper limit of normal.
- Female patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing.
Exclusion
- Patient has received any other investigational agent- within 28 days of first day of study drug dosing.
- Patient with another primary malignancy except if the other primary malignancy is neither currently clinically significant nor requiring active intervention.
- Patient has another severe and/or life-threatening medical disease.
- Patient has an acute or known chronic liver disease (e.g., chronic active hepatitis, cirrhosis).
- Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.
- Patient has received chemotherapy within 4 weeks (6 weeks for nitrosourea, mitomycin-C or any antibody therapy) prior to study entry unless urgent enrollment needed and approved by Novartis.
- Patient had a major surgery within 2 weeks prior to study entry.
- Patients with symptomatic brain metastasis.
- Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (e.g. congestive heart failure, myocardial infarction within 6 months of study)
- Medical, social or psychological factors interfering with compliance.
- Patients under therapeutic coumadin therapy.
- Patients under routine systemic corticosteroid therapy.
Key Trial Info
Start Date :
December 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2010
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00183833
Start Date
December 1 2002
End Date
August 1 2010
Last Update
May 22 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
USC/Norris Cancer Center
Los Angeles, California, United States, 90033